GO:1900004 negative regulation of serine-type endopeptidase activity: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900004 describes any biological process that stops, prevents, or reduces the activity of serine-type endopeptidases, a large family of enzymes that cleave peptide bonds using a serine residue in their active site.
• Serine-type endopeptidases include coagulation factors, digestive enzymes, and kallikrein-related peptidases; their negative regulation is critical for preventing excessive proteolysis in blood, tissues, and inflammatory sites.
• Regulation can occur at multiple levels: gene expression (e.g., carbon-source repression of PrtT-target proteases in Aspergillus niger), zymogen activation, and inhibition by endogenous protease inhibitors.
• Dysregulated serine protease activity is linked to cancer invasion, tuberculosis immunopathology, and thrombotic disorders, making negative regulation a therapeutic target.
• Key experimental models for studying GO:1900004 include knockout and point-mutation cell lines, overexpression systems, and CRISPR library screens targeting protease and inhibitor genes.
• EDITGENE provides end-to-end CRISPR services—knockout, point mutation, knock-in, overexpression, and library screening—to dissect the negative regulation of serine-type endopeptidases in disease models.
Description
Serine-type endopeptidases are a ubiquitous class of proteolytic enzymes that use a catalytic serine residue to hydrolyze peptide bonds. They participate in diverse physiological processes including blood coagulation, immune defense, tissue remodeling, and digestion. Because uncontrolled proteolysis can damage tissues and propagate disease, cells have evolved multiple layers of negative regulation to keep these enzymes in check. GO:1900004, negative regulation of serine-type endopeptidase activity, captures any process that stops, prevents, or reduces the frequency, rate, or extent of serine-type endopeptidase activity. This term is essential for understanding how organisms balance proteolytic capacity with protection against excessive cleavage. For researchers, GO:1900004 provides a framework to study protease inhibitors, zymogen activation checkpoints, and transcriptional repression of protease genes. The autolytic regulation of human kallikrein-related peptidase 6 (KLK6) exemplifies how intrinsic mechanisms can limit protease activity. Similarly, carbon-source-dependent repression of PrtT-target proteases in Aspergillus niger demonstrates transcriptional negative regulation of secreted serine proteases. In blood-contacting medical devices, polymer-coated cardiopulmonary bypass circuits attenuate the upregulation of both proteases and protease inhibitors, highlighting the clinical relevance of balancing protease activity. This article integrates QuickGO annotation data with verified PubMed literature to provide a research-grade overview of GO:1900004, its mechanisms, key genes, disease connections, and experimental strategies.
negative regulation of serine-type endopeptidase activity At A Glance
| GO ID | GO:1900004 |
|---|---|
| GO term | negative regulation of serine-type endopeptidase activity |
| Ontology | biological_process |
| Synonym | down regulation of blood coagulation factor activity; down regulation of serine-type endopeptidase activity; negative regulation of blood coagulation factor activity |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of serine-type endopeptidase activity. |
| Related protease family | Serine-type endopeptidases (e.g., kallikrein-related peptidases, coagulation factors, MASP-2) |
| Regulatory layers | Transcriptional repression, zymogen activation control, endogenous inhibitors, autolysis |
| Disease relevance | Cancer invasion, tuberculosis, thrombotic disorders, inflammatory conditions |
| Experimental models | Knockout, point mutation, knock-in, overexpression cell lines; CRISPR library screens |
What Is GO:1900004?
GO:1900004 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of serine-type endopeptidase activity. In practical terms, it encompasses molecular events such as protease inhibitor binding, transcriptional repression of protease genes, zymogen inactivation, and autolytic degradation that collectively lower the catalytic output of serine proteases. The term is not restricted to a single mechanism or cellular location; it applies whenever a serine-type endopeptidase's ability to cleave substrates is negatively modulated. Synonyms include down regulation of blood coagulation factor activity, down regulation of serine-type endopeptidase activity, and negative regulation of blood coagulation factor activity, reflecting its historical association with coagulation cascade control.
Why Is negative regulation of serine-type endopeptidase activity Important in Cell Biology?
Negative regulation of serine-type endopeptidase activity is fundamental to health because excessive or misplaced proteolysis can degrade extracellular matrix, activate pro-inflammatory pathways, and promote thrombosis. For example, the autolytic regulation of KLK6 limits its own activity, and loss of such control may contribute to cancer progression. In tuberculosis, MASP-2, a serine protease involved in complement activation, is a candidate for immune modulation, and its regulation could influence disease outcome. In cardiovascular procedures, polymer-coated bypass circuits reduce the upregulation of proteases and protease inhibitors, indicating that controlling protease activity is clinically beneficial. Understanding GO:1900004 helps researchers identify therapeutic targets, design protease inhibitors, and interpret genomic data related to protease networks.
• Prevents excessive blood coagulation by downregulating coagulation factor activity.
• Limits tissue damage from uncontrolled proteolysis in inflammation and infection.
• Controls cancer cell invasion by regulating protease-dependent extracellular matrix degradation.
• Modulates immune responses through complement serine proteases such as MASP-2.
• Enables fungal adaptation by repressing secreted proteases in response to carbon sources.
• Provides a mechanism for self-limitation of protease activity via autolysis, as seen for KLK6.
• Influences reproductive traits, as suggested by SNP associations with age at first calving in cattle.
• Serves as a target for therapeutic intervention in thrombosis and inflammatory diseases.
• Guides CRISPR screening strategies to identify negative regulators of serine proteases.
• Facilitates comparative genomics of protease regulation across species.
What Happens During negative regulation of serine-type endopeptidase activity?
Transcriptional repression of protease genes
In simple terms: The cell makes fewer protease proteins by turning down the genes that encode them.
Negative regulation can begin at the level of transcription. In Aspergillus niger, the transcription factor PrtT controls the expression of secreted proteases, and its target protease profiles are negatively regulated by carbon sources. This means that when preferred carbon sources are available, the fungus represses protease production, conserving energy and preventing unnecessary proteolysis. Similar transcriptional mechanisms likely operate in higher eukaryotes, where promoter methylation or repressor binding can reduce serine protease gene expression.
Zymogen activation checkpoints
In simple terms: Proteases are made as inactive precursors and must be switched on; blocking that switch stops activity.
Many serine-type endopeptidases, including coagulation factors and digestive enzymes, are synthesized as inactive zymogens. Negative regulation can occur by preventing the proteolytic cleavage that converts the zymogen to its active form. For example, the complement serine protease MASP-2 requires activation to participate in the lectin pathway; interfering with its activation would reduce downstream complement activity. This checkpoint ensures that proteases are only active when and where needed.
Inhibition by endogenous protease inhibitors
In simple terms: Special inhibitor proteins bind to proteases and block their active sites.
Serine protease inhibitors (serpins) and other inhibitor families form stable complexes with target proteases, irreversibly or reversibly blocking catalysis. In a porcine model of cardiopulmonary bypass, polymer-coated circuits attenuated the upregulation of both proteases and protease inhibitors, suggesting that the balance between proteases and their inhibitors is dynamically regulated during clinical interventions. This layer of negative regulation is crucial for limiting systemic proteolysis.
Autolytic self-limitation
In simple terms: Some proteases can cut themselves, which shuts down their own activity.
Human kallikrein-related peptidase 6 (KLK6) undergoes autolytic regulation, meaning it can cleave itself to reduce its own activity. This intrinsic negative feedback prevents prolonged proteolysis even when the protease is secreted. Autolysis represents a self-contained mechanism that does not require external inhibitors.
Protease-dependent invasive phenotypes and their suppression
In simple terms: Cancer cells use proteases to invade; blocking those proteases reduces invasion.
Downstream Ras signals can induce alternative protease-dependent invasive phenotypes in cancer cells. Negative regulation of serine-type endopeptidases in this context would suppress invasion by reducing the activity of proteases that degrade the extracellular matrix. Understanding these pathways may reveal targets for anti-invasive therapies.
Key Genes Involved in GO:1900004 negative regulation of serine-type endopeptidase activity
The following genes and proteins are directly or indirectly involved in the negative regulation of serine-type endopeptidase activity, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KLK6 | Kallikrein-related peptidase 6; undergoes autolytic regulation to limit its own activity | Model for intrinsic negative regulation; cancer biomarker |
| MASP-2 | Complement serine protease; activation is a checkpoint for negative regulation | Target for tuberculosis and complement-mediated diseases |
| PrtT | Transcription factor controlling protease gene expression in Aspergillus niger; negatively regulated by carbon sources | Fungal protease regulation and biotechnology |
| Coagulation factors (e.g., thrombin, factor Xa) | Serine proteases in the coagulation cascade; their activity is downregulated by inhibitors | Thrombosis research; cardiopulmonary bypass models |
| Serpins (e.g., antithrombin, alpha-1 antitrypsin) | Endogenous inhibitors that block serine protease active sites | Therapeutic targets for coagulation and inflammatory disorders |
| Ras pathway components | Induce protease-dependent invasive phenotypes; negative regulators may suppress invasion | Cancer invasion and metastasis studies |
| Candidate genes for age at first calving (e.g., protease-related SNPs) | Associated with reproductive traits in Nellore cows | Livestock genomics; protease regulation in reproduction |
| Protease inhibitors upregulated in bypass circuits | Attenuate protease activity during cardiopulmonary bypass | Biomaterial compatibility and clinical perfusion |
| Autolysis-related domains in KLK6 | Mediate self-cleavage and inactivation | Protein engineering of stable proteases |
| Carbon-source responsive elements | Mediate repression of PrtT-target proteases | Fungal gene regulation and industrial enzyme production |
| Complement pathway regulators | Control MASP-2 activity | Immunomodulation in infectious diseases |
| Extracellular matrix components | Substrates of invasive proteases; their degradation is reduced by negative regulation | Cancer microenvironment studies |
| Platelet degranulation factors | Influenced by protease/protease inhibitor balance in bypass | Hemostasis and thrombosis research |
| Zymogen activation proteases | Activate pro-proteases; their inhibition prevents downstream activity | Drug discovery for serine protease pathways |
| Transcription repressors of protease genes | Reduce protease mRNA levels | Epigenetic and transcriptional regulation studies |
| Protease-activated receptors (PARs) | Mediate downstream signaling of serine proteases; negative regulation reduces PAR activation | Inflammation and cancer signaling |
| Tissue inhibitors of metalloproteinases (TIMPs) cross-talk | Indirectly modulate serine protease networks | Protease network analysis |
| SNP variants in protease loci | Associated with reproductive traits | Genomic selection in cattle |
How Is negative regulation of serine-type endopeptidase activity Regulated?
The negative regulation of serine-type endopeptidase activity is itself regulated at multiple levels. Transcriptionally, carbon sources repress PrtT-target proteases in Aspergillus niger, linking nutrient availability to protease expression. In mammals, the Ras signaling pathway can induce protease-dependent invasive phenotypes, implying that oncogenic signals may override negative regulation. Protease inhibitors such as serpins provide a post-translational layer, and their upregulation during cardiopulmonary bypass indicates dynamic feedback. Autolytic regulation, as seen for KLK6, represents a self-regulatory loop that is intrinsic to the protease. Together, these mechanisms form a network that can be modulated by metabolic state, inflammation, and genetic alterations.
negative regulation of serine-type endopeptidase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KLK6 | Cancer progression; autolytic regulation | KLK6 knockout and point-mutation cancer cell lines |
| MASP-2 | Tuberculosis; complement activation | MASP-2 overexpression and knockout macrophages |
| Coagulation factors | Thrombosis; cardiopulmonary bypass | Knock-in mice with modified coagulation factor cleavage sites |
| Ras pathway components | Cancer invasion | Ras-driven cancer cells with protease inhibitor overexpression |
| PrtT | Fungal protease regulation | Aspergillus niger PrtT knockout strains |
Cancer invasion and metastasis
Serine-type endopeptidases contribute to cancer cell invasion by degrading extracellular matrix components. Downstream Ras signals induce alternative protease-dependent invasive phenotypes, and negative regulation of these proteases could suppress invasion. KLK6, which undergoes autolytic regulation, is implicated in cancer, and loss of its self-limiting activity may enhance tumor progression. Targeting the negative regulatory mechanisms could therefore be a therapeutic strategy.
Tuberculosis and complement-mediated immunity
MASP-2 is a serine protease in the complement lectin pathway. A study constructed human MASP-2-CCP1/2SP, CCP2SP, and SP plasmid DNA nanolipoplexes and evaluated their effects on tuberculosis in BCG-infected mice, suggesting that modulating MASP-2 activity may influence immune responses to Mycobacterium tuberculosis. Negative regulation of MASP-2 could thus affect disease outcome.
Thrombotic and cardiovascular disorders
Coagulation factors are serine-type endopeptidases, and their negative regulation prevents excessive clotting. In a porcine model, polymer-coated cardiopulmonary bypass circuits attenuated the upregulation of both proteases and protease inhibitors, indicating that clinical interventions can perturb the balance. Dysregulation of these negative regulatory mechanisms may contribute to thrombosis or bleeding disorders.
Fungal pathogenesis and biotechnology
In Aspergillus niger, the transcription factor PrtT and its target protease profiles are negatively regulated by carbon sources. This regulation is important for fungal adaptation and has implications for industrial enzyme production and fungal pathogenesis. Understanding negative regulation could lead to strategies for controlling fungal proteases.
From negative regulation of serine-type endopeptidase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of KLK6 autolysis increase invasive potential? | KLK6 point-mutation (autolysis-resistant) knock-in cancer cell line |
| Does MASP-2 inhibition reduce tuberculosis burden? | MASP-2 knockout mice infected with BCG |
| How does carbon source affect PrtT-target protease expression? | Aspergillus niger PrtT knockout and overexpression strains |
| Can overexpression of a serpin reduce bypass-induced proteolysis? | Pig model with serpin-overexpressing endothelial cells |
| Which genes negatively regulate Ras-induced protease invasion? | CRISPR library screen in Ras-transformed cells |
| Does a SNP in a protease locus affect calving age? | Knock-in cattle models or cell lines with the SNP |
How to Study the negative regulation of serine-type endopeptidase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | mRNA levels of proteases and inhibitors | Transcriptional negative regulation |
| Protease activity assay | Catalytic activity of serine proteases | Autolysis and inhibition studies |
| Proteomics | Protein abundance and complexes | Inhibitor profiling in clinical samples |
| CRISPR knockout screen | Genes affecting protease activity | Discovery of negative regulators |
| CRISPR activation screen | Overexpression effects on protease activity | Identifying suppressors of invasion |
| Site-directed mutagenesis | Specific residues in protease active sites | Autolysis-resistant KLK6 |
| Plasmid DNA nanolipoplex delivery | Expression of MASP-2 constructs in vivo | Tuberculosis immune modulation |
| SNP genotyping | Genetic variants associated with traits | Age at first calving in cattle |
Transcriptomic profiling of protease and inhibitor genes
RNA-seq can quantify changes in mRNA levels of serine proteases and their inhibitors under conditions that induce or repress negative regulation. For example, carbon-source-dependent repression of PrtT-target proteases in Aspergillus niger was studied using expression profiling. In mammals, RNA-seq of cancer cells with activated Ras can reveal protease networks.
Protease activity assays
Enzymatic assays using chromogenic or fluorogenic substrates measure the catalytic activity of serine-type endopeptidases directly. Such assays can detect autolytic regulation of KLK6 or the inhibitory effects of serpins. They are essential for validating negative regulation at the protein level.
Proteomics and inhibitor profiling
Mass spectrometry-based proteomics can identify protease-inhibitor complexes and quantify changes in protease abundance. In cardiopulmonary bypass studies, proteomic approaches revealed upregulation of both proteases and protease inhibitors. Activity-based protein profiling (ABPP) can specifically label active serine proteases.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes whose loss or gain affects serine protease activity. For instance, screening for negative regulators of Ras-induced invasion could uncover new protease inhibitors. Such screens are powerful for discovering unanticipated regulatory components.
How CRISPR Can Be Used to Study GO:1900004 negative regulation of serine-type endopeptidase activity
Knockout
CRISPR knockout of genes encoding serine proteases or their negative regulators can reveal their contribution to cellular phenotypes. For example, knocking out KLK6 would test whether loss of autolytic regulation increases invasive capacity. Knocking out PrtT in Aspergillus niger would de-repress protease expression, confirming its role in carbon-source repression.
Point Mutation
Point mutations can abrogate specific regulatory sites, such as the autolysis loop in KLK6, without deleting the entire gene. This allows precise dissection of negative regulation mechanisms. Similarly, point mutations in the MASP-2 active site could clarify its role in complement activation.
Knock-in
Knock-in of tagged or mutant versions of protease genes enables tracking and functional analysis. For instance, knocking in a fluorescently tagged KLK6 would allow live-cell imaging of autolysis. Knock-in of human MASP-2 into mouse models could facilitate tuberculosis studies.
Overexpression
Overexpression of serine protease inhibitors or negative regulatory proteins can suppress protease activity. For example, overexpressing a serpin in endothelial cells might reduce bypass-induced proteolysis. Overexpression of PrtT targets could overwhelm the negative regulation by carbon sources.
How EDITGENE Supports negative regulation of serine-type endopeptidase activity Research
Researchers studying negative regulation of serine-type endopeptidase activity-related genes often need to determine whether a candidate gene is causally involved in controlling protease activity, or whether it is merely a biomarker. Establishing causality requires precise genetic manipulation, which is where EDITGENE's CRISPR services become indispensable.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of serine-type endopeptidase activity research.
Frequently Asked Questions About negative regulation of serine-type endopeptidase activity
What is GO:1900004?
GO:1900004 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of serine-type endopeptidase activity.
What are serine-type endopeptidases?
They are enzymes that cleave peptide bonds using a serine residue in their active site. Examples include kallikrein-related peptidases, coagulation factors, and complement proteases like MASP-2.
What genes are involved in negative regulation of serine-type endopeptidase activity?
Key genes include KLK6 (autolytic regulation), MASP-2 (complement activation), PrtT (transcriptional repression in fungi), and serpins (endogenous inhibitors).
How is serine-type endopeptidase activity negatively regulated?
Mechanisms include transcriptional repression, zymogen activation checkpoints, inhibition by serpins, and autolytic self-cleavage.
Why is negative regulation of serine proteases important in cancer?
Uncontrolled serine protease activity promotes cancer invasion by degrading extracellular matrix. Negative regulation suppresses this process, and its loss may enhance metastasis.
What diseases are linked to dysregulated serine protease activity?
Thrombotic disorders, tuberculosis, cancer, and inflammatory conditions have been associated with altered serine protease regulation.
How can CRISPR be used to study GO:1900004?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of protease and inhibitor genes to test their role in negative regulation.
What model organisms are used to study negative regulation of serine proteases?
Models include human cell lines, mice, pigs, cattle, and Aspergillus niger, depending on the biological question.
What is autolytic regulation of KLK6?
KLK6 can cleave itself to reduce its own activity, serving as an intrinsic negative feedback mechanism.
How does carbon source affect protease regulation in Aspergillus niger?
The transcription factor PrtT and its target protease profiles are negatively regulated by carbon sources, meaning preferred carbon sources repress protease production.
Conclusion
GO:1900004, negative regulation of serine-type endopeptidase activity, is a critical biological process that safeguards cells and organisms from excessive proteolysis. Its mechanisms span transcriptional repression, zymogen checkpoints, inhibitor binding, and autolysis, with key players such as KLK6, MASP-2, PrtT, and serpins. Dysregulation of this process contributes to cancer, tuberculosis, and thrombotic disorders, making it a rich area for therapeutic targeting. By leveraging CRISPR-based knockout, point mutation, knock-in, and overexpression models, researchers can dissect these pathways with unprecedented precision. EDITGENE offers comprehensive services to support such studies, from custom cell line generation to genome-wide library screening and bioinformatics analysis.
References
- 1. Blaber SI et al.. 2007. The autolytic regulation of human kallikrein-related peptidase 6.. Biochemistry 46(17):5209-17 PMID: 17417874
- 2. Suehiro S et al.. 2017. Polymer-coated cardiopulmonary bypass circuit attenuates upregulation of both proteases/protease inhibitors and platelet degranulation in pigs.. Perfusion 32(8):645-655 PMID: 28592188
- 3. Gao Q et al.. 2017. Construction of human MASP-2-CCP1/2SP, CCP2SP, SP plasmid DNA nanolipoplexes and the effects on tuberculosis in BCG-infected mice.. Microb Pathog 109:200-208 PMID: 28578092
- 4. Dubon MAC et al.. 2021. Identification of novel candidate genes for age at first calving in Nellore cows using a SNP chip specifically developed for Bos taurus indicus cattle.. Theriogenology 173:156-162 PMID: 34392169
- 5. Silberman S et al.. 1997. Characterization of downstream Ras signals that induce alternative protease-dependent invasive phenotypes.. J Biol Chem 272(9):5927-35 PMID: 9038212
- 6. Huang L et al.. 2020. The transcription factor PrtT and its target protease profiles in Aspergillus niger are negatively regulated by carbon sources.. Biotechnol Lett 42(4):613-624 PMID: 31970554
